11.01.06
Pycnogenol Relieves Muscle Cramps and Pain in Athletes
A study published in Angiology has showed that supplementation with Horphag Research’s Pycnogenol pine bark extract improves blood flow to the muscles, which speeds recovery after physical exercise.
The study consisted of 66 participants, who had experienced normal cramping at some point, had venous insufficiency, or were athletes suffering from exercise-induced cramping. The first two weeks of the study represented an observation period where participants did not supplement with Pycnogenol. Symptoms related to venous disorders, and the number of cramping episodes each participant experienced over the two observation weeks were recorded. Next, all the participants were given 200 mg of Pycnogenol once a day for four weeks. After the treatment phase, participants’ symptoms and cramping episodes were recorded for one week without any Pycnogenol supplementation.
The researchers found a decrease in the number of cramps the participants experienced while supplementing with Pycnogenol. Participants who had experienced normal cramping had a 25% reduction in the number of cramps experienced while taking Pycnogenol.
Participants with venous insufficiency experienced a 40% reduction in the number of cramps, and athletes with frequent cramping experienced a 13% reduction in the number of cramps while on Pycnogenol.
For further information: 312-546-3508.
Nexrutine Inhibits Prostate Cancer Cell Proliferation
Next Pharmaceuticals, Inc. has released the results of a study funded by the National Institute of Health on the potential benefits of Nexrutine, a proprietary extract from the bark of the Phellodendron tree, on prostate cancer. Scientists at the Department of Urology at the University of Texas Health Science Center have found that this herbal extract prevents the growth of prostate cancer cells in laboratory studies. These studies also found that blocking the activation of a transcription factor called CREB and a critical cell survival signaling kinase called Akt disrupted prostate cancer cell growth and induced cell death, a balance that is altered in cancer cells.
For further information: 415-454-2243.
Keragen Shows Promising Wound Healing Benefits
Keratec Limited, Christchurch, New Zealand, and U.S.-based Keraplast Technologies Limited have successfully completed a human clinical trial on the patented Keragen range of chronic wound treatment products. The results showed sufficient promise to clear the way for further comprehensive trials.
Twenty-two patients participated in the non-randomized open-label clinical study. Seventy-seven percent of the patients showed healing improvement and 18% completely healed. Overall, 91% of the patients and 86% of nurses preferred the Keragen dressings to their usual dressings.
A study published in Angiology has showed that supplementation with Horphag Research’s Pycnogenol pine bark extract improves blood flow to the muscles, which speeds recovery after physical exercise.
The study consisted of 66 participants, who had experienced normal cramping at some point, had venous insufficiency, or were athletes suffering from exercise-induced cramping. The first two weeks of the study represented an observation period where participants did not supplement with Pycnogenol. Symptoms related to venous disorders, and the number of cramping episodes each participant experienced over the two observation weeks were recorded. Next, all the participants were given 200 mg of Pycnogenol once a day for four weeks. After the treatment phase, participants’ symptoms and cramping episodes were recorded for one week without any Pycnogenol supplementation.
The researchers found a decrease in the number of cramps the participants experienced while supplementing with Pycnogenol. Participants who had experienced normal cramping had a 25% reduction in the number of cramps experienced while taking Pycnogenol.
Participants with venous insufficiency experienced a 40% reduction in the number of cramps, and athletes with frequent cramping experienced a 13% reduction in the number of cramps while on Pycnogenol.
For further information: 312-546-3508.
Nexrutine Inhibits Prostate Cancer Cell Proliferation
Next Pharmaceuticals, Inc. has released the results of a study funded by the National Institute of Health on the potential benefits of Nexrutine, a proprietary extract from the bark of the Phellodendron tree, on prostate cancer. Scientists at the Department of Urology at the University of Texas Health Science Center have found that this herbal extract prevents the growth of prostate cancer cells in laboratory studies. These studies also found that blocking the activation of a transcription factor called CREB and a critical cell survival signaling kinase called Akt disrupted prostate cancer cell growth and induced cell death, a balance that is altered in cancer cells.
For further information: 415-454-2243.
Keragen Shows Promising Wound Healing Benefits
Keratec Limited, Christchurch, New Zealand, and U.S.-based Keraplast Technologies Limited have successfully completed a human clinical trial on the patented Keragen range of chronic wound treatment products. The results showed sufficient promise to clear the way for further comprehensive trials.
Twenty-two patients participated in the non-randomized open-label clinical study. Seventy-seven percent of the patients showed healing improvement and 18% completely healed. Overall, 91% of the patients and 86% of nurses preferred the Keragen dressings to their usual dressings.